Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

A Phase 2 Study of Epcoritamab in Patients with Follicular Lymphoma Not Achieveing a Complete Response with Front-Line Chemoimmunotherapy (EPCON)

Gottfried von Keudell, Emma K Logan, Robert A. Redd, Michael Leukam, Matthew Weinstock, Jon E. Arnason, Ranjana H. Advani

Blood (2024) 144 (Supplement 1): 6284.

https://doi.org/10.1182/blood-2024-206520

Published: 2024

Journal Articles

Infectious Complications in B-Cell Non-Hodgkin Lymphoma (NHL) Patients Treated with Bispecific Antibody Therapy (BsAb) As Compared to Chimeric Antigen Receptor T-Cell Therapy (CAR-T)

Genevieve M Gerhard, Robert A. Redd, Poorva Bindal, Carolyn D Alonso, Rushad Patell, Michael Leukam, Jon E. Arnason, Matthew Weinstock, Gottfried von Keudell

Blood (2024) 144 (Supplement 1): 6554.

https://doi.org/10.1182/blood-2024-199156

Published: 2024

Journal Articles

PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies

Blood (2024) 144 (Supplement 1): 1674.2.

https://doi.org/10.1182/blood-2024-203060

Published: 2024

Journal Articles

Infectious Complications in Patients with Hemophagocytic Lymphohistiocytosis: A Single Center Experience

Lelas Shamaileh, Sirui Ma, Matthew Weinstock

Blood (2024) 144 (Supplement 1): 5367.

https://doi.org/10.1182/blood-2024-194180

Published: 2024

Journal Articles

Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Blood (2024) 144 (Supplement 1): 1865.

https://doi.org/10.1182/blood-2024-206556

Published: 2024

Journal Articles

Rates of Trimethoprim-Sulfamethoxazole Versus Alternative Pneumocystis Prophylaxis Agents in Patients Undergoing Hematopoietic Stem Cell Transplantation

Noah Rosenberg, Matthew Weinstock, Carolyn D Alonso

Blood (2024) 144 (Supplement 1): 7378.

https://doi.org/10.1182/blood-2024-199778

Published: 2024

Journal Articles

A Randomized Phase 2 Study Incorporating Nivolumab and Brentuximab Vedotin into Radiation-Free Treatment of Early Stage Classic Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 459.

https://doi.org/10.1182/blood-2024-204113

Published: 2024

Journal Articles

Granulocyte Colony-Stimulating Factor Use in Patients with Hemophagocytic Lymphohistiocytosis: A Single Center Experience

Lelas Shamaileh, Sirui Ma, Matthew Weinstock

Blood (2023) 142 (Supplement 1): 1171.

https://doi.org/10.1182/blood-2023-186146

Published: 2023

Journal Articles

Final Results of a Multicenter Pilot Study Evaluating Brentuximab Vedotin with Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the Treatment of Aggressive Adult T-Cell Leukemia/Lymphoma

Christopher Dittus, Matthew Weinstock, Jeffrey A. Barnes, Jose Sandoval-Sus, Natalie S. Grover, Anne Beaven, Xianming Tan, Areej El-Jawahri, Shayna R Sarosiek, John Mark Sloan

Blood (2023) 142 (Supplement 1): 1692.

https://doi.org/10.1182/blood-2023-173822

Published: 2023

Journal Articles

Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)

Matthew S. Davids, MD, Benjamin L. Lampson, MD PhD, Svitlana Tyekucheva, PhD, Jennifer L. Crombie, MD, Samuel Ng, MD PhD, Austin I. Kim, MD, Matthew Weinstock, MD, Jessica Lowney, Samantha Pazienza, Josie Montegaard, NP, Victoria Patterson, BSN, RN, Caron A. Jacobson, MD, Ann S. LaCasce, MD MSc, Philippe Armand, MD PhD, Jon E. Arnason, MD, David C. Fisher, MD, Jennifer R. Brown, MD PhD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-139864

Published: 2020

Journal Articles

Development of Novel Second Generation DC/Tumor Fusion Vaccine in Lymphoma

Shira Orr, PhD, Marzia Capelletti, PhD MBBS, Haider Ghiasuddin, Dina Stroopinsky, PhD, Jessica Liegel, MD, Myrna Nahas, MD, Matthew Weinstock, MD, Adam Morin, Robin M. Joyce, MD, Salvia Jain, MD, Jon E. Arnason, MD, Maryam Rahimian, MD, Lina Bisharat, Shufen Meng, MD, Donald Kufe, MD, Jacalyn Rosenblatt, MD, David E. Avigan, MD

Blood (2019) 134 (Supplement_1): 392.

https://doi.org/10.1182/blood-2019-124768

Published: 2019

Journal Articles

Transcriptome Sequencing Demonstrates Unique Signature Associated with Durable Clinical Response to DC/AML Fusion Vaccine

Blood (2019) 134 (Supplement_1): 3832.

https://doi.org/10.1182/blood-2019-129451

Published: 2019

Journal Articles

T Cells Educated By DC/AML Fusions in the Context of 4-1BB Costimulation As a Potent Strategy for Adoptive Cellular Therapy

Jessica Liegel, MD, Dina Stroopinsky, PhD, Haider Ghiasuddin, Adam Morin, Marzia Capelletti, PhD MMSc, Shira Orr, PhD, Maryam Rahimian, MD, Lina Bisharat, Shufen Meng, MD, Myrna Nahas, MD, Matthew Weinstock, MD, Donald Kufe, MD, Jacalyn Rosenblatt, MD, David E. Avigan, MD

Blood (2019) 134 (Supplement_1): 2673.

https://doi.org/10.1182/blood-2019-131491

Published: 2019

Journal Articles

Ex-Vivo Stimulation with DC/AML Fusion Vaccine in the Presence of Cytokines Leads to an Activated T Cell Memory Phenotype and Enhanced Cytotoxicity with Potential for Use As an Adoptive Cellular Therapy

Jessica Liegel, MD, Dina Stroopinsky, PhD, Lourdes M. Mendez, MD PhD, Malgorzata McMasters, MD, Haider Ghiasuddin, BA, Maryam Rahimian, MD, Myrna Nahas, MD, Matthew Weinstock, MD, Salvia Jain, MD, Marzia Capelletti, PhD MMSc, Lina Bisharat, MA, Adam Morin, BA, Shira Orr, PhD, Jacalyn Rosenblatt, MD, Donald Kufe, MD, David E. Avigan, MD

Blood (2018) 132 (Supplement 1): 2728.

https://doi.org/10.1182/blood-2018-99-119996

Published: 2018

Journal Articles

A Novel Monoclonal Antibody Combination Plus DC/AML Fusion Vaccine Eradicates AML in an Immunocompetent Murine Model

Dina Stroopinsky, PhD, Jessica Liegel, MD, Kathleen M. Mahoney, MD PhD, Jacalyn Rosenblatt, MD, Benjamin L. Ebert, MD PhD, Richard M. Stone, MD, Maryam Rahimian, MD, Myrna Nahas, MD, Shira Orr, PhD, Marzia Capelletti, PhD MMSc, Matthew Weinstock, MD, Salvia Jain, MD, Lina Bisharat, MA, Haider Ghiasuddin, BA, Adam Morin, BA, Donald Kufe, MD, Gordon J Freeman, PhD, David E. Avigan, MD

Blood (2018) 132 (Supplement 1): 1446.

https://doi.org/10.1182/blood-2018-99-120259

Published: 2018

Journal Articles

Hypomethylating Agent Leads to Enhanced Immunogenicity of a Dendritic Cell/Acute Myeloid Leukemia Fusion Vaccine and Prolonged Survival in an Immunocompetent Mouse Model

Myrna R. Nahas, MD, Leandra Cole, Dina Stroopinsky, PhD, Anna Sergeeva, PhD, Athalia Rachel Pyzer, MD PhD, Abigail J. Washington, Malgorzata McMasters, MD, James D. Levine, MD MS, Matthew Weinstock, MD, Shira Orr, PhD, Adam Ephraim, Jeffrey J. Molldrem, MD, Jacalyn Rosenblatt, MD, David E. Avigan, MD

Blood (2017) 130 (Supplement 1): 1347.

https://doi.org/10.1182/blood.V130.Suppl_1.1347.1347

Published: 2017

Journal Articles

Time to Development of Treatment-Emergent Extramedullary and Osseous Plasmacytomas in the Era of Novel Agents: An Analysis of Upfront Regimens in Newly Diagnosed MM Incorporating Lenalidomide and Bortezomib

Cindy Varga, Jacob P. Laubach, MD, Irene M. Ghobrial, MD, Matthew Weinstock, MD, Claudia E. Paba-Prada, MD, Robert L. Schlossman, MD, Nikhil Munshi, Wanling Xie, MS, Edie A. Weller, PhD, Kenneth C. Anderson, MD, Constantine S. Mitsiades, MD PhD, Paul G. Richardson

Blood (2014) 124 (21): 3468.

https://doi.org/10.1182/blood.V124.21.3468.3468

Published: 2014

Journal Articles

Incidence and Clinical Features of Extramedullary Multiple Myeloma in Patients Who Underwent Stem Cell Transplantation

Matthew Weinstock, MD, Yosra Aljawai, MS, Irene M. Ghobrial, MD, Elizabeth A. Morgan, MD, Jacob P. Laubach, MD, Aldo M Roccaro, MD PhD, Cindy Varga, Muriel Gannon, RN, Claudia E. Paba-Prada, MD, Robert L Schlossman, MD, Nikhil Munshi, Kenneth C. Anderson, Paul G. Richardson, Constantine S. Mitsiades, MD PhD

Blood (2014) 124 (21): 5746.

https://doi.org/10.1182/blood.V124.21.5746.5746

Published: 2014

NARROW

A Phase 2 Study of Epcoritamab in Patients with Follicular Lymphoma Not Achieveing a Complete Response with Front-Line Chemoimmunotherapy (EPCON)

Infectious Complications in B-Cell Non-Hodgkin Lymphoma (NHL) Patients Treated with Bispecific Antibody Therapy (BsAb) As Compared to Chimeric Antigen Receptor T-Cell Therapy (CAR-T)

PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies

Infectious Complications in Patients with Hemophagocytic Lymphohistiocytosis: A Single Center Experience

Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Rates of Trimethoprim-Sulfamethoxazole Versus Alternative Pneumocystis Prophylaxis Agents in Patients Undergoing Hematopoietic Stem Cell Transplantation

A Randomized Phase 2 Study Incorporating Nivolumab and Brentuximab Vedotin into Radiation-Free Treatment of Early Stage Classic Hodgkin Lymphoma

Granulocyte Colony-Stimulating Factor Use in Patients with Hemophagocytic Lymphohistiocytosis: A Single Center Experience

Final Results of a Multicenter Pilot Study Evaluating Brentuximab Vedotin with Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the Treatment of Aggressive Adult T-Cell Leukemia/Lymphoma

Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)

Development of Novel Second Generation DC/Tumor Fusion Vaccine in Lymphoma

Transcriptome Sequencing Demonstrates Unique Signature Associated with Durable Clinical Response to DC/AML Fusion Vaccine

T Cells Educated By DC/AML Fusions in the Context of 4-1BB Costimulation As a Potent Strategy for Adoptive Cellular Therapy

Ex-Vivo Stimulation with DC/AML Fusion Vaccine in the Presence of Cytokines Leads to an Activated T Cell Memory Phenotype and Enhanced Cytotoxicity with Potential for Use As an Adoptive Cellular Therapy

A Novel Monoclonal Antibody Combination Plus DC/AML Fusion Vaccine Eradicates AML in an Immunocompetent Murine Model

Hypomethylating Agent Leads to Enhanced Immunogenicity of a Dendritic Cell/Acute Myeloid Leukemia Fusion Vaccine and Prolonged Survival in an Immunocompetent Mouse Model

Time to Development of Treatment-Emergent Extramedullary and Osseous Plasmacytomas in the Era of Novel Agents: An Analysis of Upfront Regimens in Newly Diagnosed MM Incorporating Lenalidomide and Bortezomib

Incidence and Clinical Features of Extramedullary Multiple Myeloma in Patients Who Underwent Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only